Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Valganciclovir Hydrochloride

FDA-approved product (tablet, oral), marketed as Valcyte, Valganciclovir Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Valganciclovir Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • AIDS
  • Cytomegalovirus Retinitis
  • Retinitis
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AB14

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Valganciclovir Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Valganciclovir Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

    NCT07138989 · start 2025-08-19

    Registered record
    Registry ID
    NCT07138989
    Conditions
    Nasopharyngeal Cancinoma (NPC)
    Interventions
    Valganciclovir Hydrochloride Tablets; gemcitabine, cisplatin, and PD-1 antibody
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-08-19
    Completion
    2031-08-18
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNasopharyngeal Cancinoma (NPC)
    InterventionValganciclovir Hydrochloride Tablets; gemcitabine, cisplatin, and PD-1 antibody
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

    NCT06439342 · start 2024-12-16

    Registered record
    Registry ID
    NCT06439342
    Conditions
    Cytomegalovirus (CMV)
    Interventions
    Maribavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-12-16
    Completion
    2026-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus (CMV)
    InterventionMaribavir
    PhasePhase 3
    Registry statusRecruiting

  • A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea

    NCT06555432 · start 2024-11-14

    Registered record
    Registry ID
    NCT06555432
    Conditions
    Cytomegalovirus (CMV)
    Interventions
    LIVTENCITY
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-11-14
    Completion
    2028-10-01
    Enrolment
    168

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus (CMV)
    InterventionLIVTENCITY
    PhaseNot recorded
    Registry statusRecruiting

  • A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma

    NCT06102525 · start 2024-10-08

    Registered record
    Registry ID
    NCT06102525
    Conditions
    Glioblastoma
    Interventions
    RZ-001; VGCV
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-10-08
    Completion
    2029-05
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma
    InterventionRZ-001; VGCV
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients

    NCT07430683 · start 2024-03-01

    Registered record
    Registry ID
    NCT07430683
    Conditions
    Cytomegalovirus Infections
    Interventions
    Valganciclovir Prophylaxis; Preemptive Therapy (CMV PCR Monitoring)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2024-03-01
    Completion
    2026-07-31
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections
    InterventionValganciclovir Prophylaxis; Preemptive Therapy (CMV PCR Monitoring)
    PhasePhase 4
    Registry statusActive not recruiting

  • Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.

    NCT06057194 · start 2023-10

    Registered record
    Registry ID
    NCT06057194
    Conditions
    Infections, Cytomegalovirus
    Interventions
    Letermovir 240 mg Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2023-10
    Completion
    2027-04
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Cytomegalovirus
    InterventionLetermovir 240 mg Oral Tablet
    PhasePhase 2
    Registry statusNot yet recruiting

  • CMV CTLs in Neonates With CMV Infection

    NCT05564598 · start 2023-07-01

    Registered record
    Registry ID
    NCT05564598
    Conditions
    Congenital Cytomegaloviral (CMV) Disease
    Interventions
    CMV Cytotoxic T-Lymphocytes; Anti-viral Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-07-01
    Completion
    2028-10-31
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Cytomegaloviral (CMV) Disease
    InterventionCMV Cytotoxic T-Lymphocytes; Anti-viral Therapy
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma

    NCT05595473 · start 2022-07-29

    Registered record
    Registry ID
    NCT05595473
    Conditions
    Hepatocellular Carcinoma
    Interventions
    RZ-001 Dose 1; RZ-001 Dose 2; RZ-001 Dose 3; RZ-001 Dose 4
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2022-07-29
    Completion
    2029-05
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    InterventionRZ-001 Dose 1; RZ-001 Dose 2; RZ-001 Dose 3; RZ-001 Dose 4
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Pilot Study of Antiviral Treatment in Combination With Low-dose Gemcitabine in EBV-associated Gastric Cancer (EBVaGC)

    NCT05431244 · start 2022-07-01

    Registered record
    Registry ID
    NCT05431244
    Conditions
    Gastric Cancer
    Interventions
    Antiviral treatment in combination with low-dose gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2022-07-01
    Completion
    2024-07-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Cancer
    InterventionAntiviral treatment in combination with low-dose gemcitabine
    PhaseNot applicable
    Registry statusWithdrawn

  • Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy

    NCT04064697 · start 2021-04-22

    Registered record
    Registry ID
    NCT04064697
    Conditions
    Ulcerative Colitis, Unspecified
    Interventions
    Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-04-22
    Completion
    2024-02-08
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis, Unspecified
    InterventionValganciclovir
    PhasePhase 3
    Registry statusTerminated

  • Breakthrough CMV Lung Transplant -Multicentre

    NCT04439916 · start 2021-01-25

    Registered record
    Registry ID
    NCT04439916
    Conditions
    Cytomegalovirus Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-01-25
    Completion
    2027-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • Asymptomatic Congenital CMV Treatment

    NCT03301415 · start 2019-08-21

    Registered record
    Registry ID
    NCT03301415
    Conditions
    Congenital Cytomegalovirus Infection
    Interventions
    Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-08-21
    Completion
    2020-11-05
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Cytomegalovirus Infection
    InterventionValganciclovir
    PhasePhase 2
    Registry statusTerminated

  • Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

    NCT03511118 · start 2018-10-04

    Registered record
    Registry ID
    NCT03511118
    Conditions
    Lactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    Interventions
    Tranexamic acid (TXA); labetalol; metformin; nifedipine; clindamycin; oxycodone; azithromycin; escitalopram; sertraline; ondansetron; Ciprofloxacin; Doxycycline; Levofloxacin; Methylphenidate; Sumatriptan; Citalopram; Cyclobenzaprine; Furosemide; Gabapentin; Hydrochlorothiazide; Hydroxyurea; Rosuvastatin; Topiramate; Trazodone; Valganciclovir; Venlafaxine; Verapamil; Remdesivir; Anakinra; Tocilizumab; Fluvoxamine; Amoxicillin; Bupropion; Duloxetine; Hydrocodone; Levetiracetam; Paroxetine; Buprenorphine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-10-04
    Completion
    2028-07-31
    Enrolment
    1,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    InterventionTranexamic acid (TXA); labetalol; metformin; nifedipine +34 more
    PhaseNot recorded
    Registry statusRecruiting

  • (Val)Ganciclovir TDM in Transplant Recipients

    NCT03698435 · start 2018-05-25

    Registered record
    Registry ID
    NCT03698435
    Conditions
    Cytomegalovirus Infections
    Interventions
    Ganciclovir; Valganciclovir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-05-25
    Completion
    2019-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections
    InterventionGanciclovir; Valganciclovir
    PhaseNot recorded
    Registry statusUnknown